913b THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
Jessica R. Allegretti(Brigham and Women's Hospital), David T. Rubin(University of California System), Gary R. Lichtenstein, Tadakazu Hisamatsu(Kyorin University), Julián Panés(Hospital Clínic de Barcelona), Axel Dignaß(Goethe University Frankfurt), Laurent Peyrin‐Biroulet(Délégation Centre-Est), Brian G. Feagan(Western University), Brian Bressler(University of British Columbia), Lingjing Jiang(University of California San Diego), Nicole Shipitofsky(Janssen (United States)), Kuan‐Hsiang Gary Huang(Janssen (United States)), Matthew Germinaro(Johnson & Johnson (United States)), Hongyan Zhang(Northwest A&F University), Bruce E. Sands(Icahn School of Medicine at Mount Sinai)
Cited by 9
Related Papers
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
|Nature Biotechnology|2019|24.7k
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
A communal catalogue reveals Earth’s multiscale microbial diversity
|Nature|2017|2.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k